"For patients with nonmetastatic prostate cancer, the optimal sequencing of short-term androgen-deprivation therapy (ADT) when delivered with radiotherapy (RT) has been uncertain. Only two randomized trials have investigated this question. Now, however, a study in the Journal of Clinical Oncology, has provided more definitive evidence.
Amar Kishan, MD, of the University of California Los Angeles, and colleagues pooled individual data from 7,409 patients in 12 randomized trials. The patients were treated with RT and short-term neoadjuvant/concurrent ADT (n=6,325) or concurrent/adjuvant ADT (n=1,084), and outcomes were examined by RT field size.
In men who received prostate-only radiotherapy (PORT), concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, HR 0.65, P<0.0001) and overall survival (HR 0.69, P<0.0001).
"These data strongly suggest that when PORT is being delivered with short-term ADT -- as is recommended for men with intermediate-risk disease -- concurrent/adjuvant ADT sequencing should be the standard of care," the researchers concluded."